BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 3, 2012
View Archived Issues
GlaxoSmithKline reviews second quarter 2012
Read More
Alla Chem patents novel receptor ligands
Read More
Curagenix synthesizes new inhibitors of Wnt signaling
Read More
New phase I-II data disclosed on renal cell carcinoma vaccine candidate
Read More
Genetically corrected human iPSC-derived mesoangioblast as potential muscular dystrophy therapy
Read More
Three-peptide vaccine for advanced esophageal cancer shows promise in phase I-II trials
Read More
New complement factor D inhibitors prepared at Novartis
Read More
Kinentia Biosciences presents new ERK-2/MMP-1 inhibitors
Read More
Eisai discloses new BACE1 inhibitors
Read More
Microbiotix receives grant to develop type III secretion inhibitors
Read More
OrPro Therapeutics awarded NIH grant to advance recombinant thioredoxin
Read More
BMS-986094 administration suspended in clinical trial
Read More
BromSite advances to phase III testing
Read More
Agios Pharmaceuticals divulges novel PKM2 activators
Read More
Hologic completes acquisition
Read More
BioTime subsidiary receives grant from Israeli government
Read More
Novel DLL4-directed antibodies reported
Read More
FDA accepts Bronchitol NDA for review
Read More
Novel antibodies designed by researchers in Cuba and Uruguay
Read More
First patients treated in two lung cancer trials evaluating ganetespib
Read More
Two investigator-sponsored cabozantinib trials begin
Read More
Asterand changes name
Read More
Diffusion Pharmaceuticals completes treatment in first cohort of phase I/II brain cancer trial
Read More
Studies of Cinryze/rHuPH20 combination placed on temporary hold
Read More
DBV Technologies kicks off phase IIb VIPES study
Read More
Acquisition of Human Genome Sciences complete
Read More
Additional funding supports development of Anthim
Read More
Oxygen Biotherapeutics and U.S. navy establish Oxycyte CRADA
Read More